Cogent Biosciences Inc Net Assets
Cogent Biosciences Inc net assets. Based on the latest financial reports, Cogent Biosciences Inc (COGT) has net assets worth $636.37 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($937.61 Million) and total liabilities ($301.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Cogent Biosciences Inc growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $636.37 Million |
| % of Total Assets | 67.87% |
| Annual Growth Rate | 24.78% |
| 5-Year Change | 197.11% |
| 10-Year Change | 1114.73% |
| Growth Volatility | 196.3 |
Net Assets of Cogent Biosciences Inc (2015–2025)
Net assets of Cogent Biosciences Inc from 2015 to 2025. This chart illustrates how Cogent Biosciences Inc's net assets have evolved over time, based on quarterly financial data. See COGT net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Cogent Biosciences Inc (2015–2025)
The table below shows the annual net assets of Cogent Biosciences Inc from 2015 to 2025. For live market cap and overall valuation, see Cogent Biosciences Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $636.37 Million | +148.31% |
| 2024-12-31 | $256.29 Million | -0.59% |
| 2023-12-31 | $257.80 Million | +0.81% |
| 2022-12-31 | $255.74 Million | +19.40% |
| 2021-12-31 | $214.18 Million | -8.73% |
| 2020-12-31 | $234.67 Million | +638.83% |
| 2019-12-31 | $31.76 Million | -47.27% |
| 2018-12-31 | $60.23 Million | +112.80% |
| 2017-12-31 | $28.30 Million | -45.97% |
| 2016-12-31 | $52.39 Million | -24.64% |
| 2015-12-31 | $69.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cogent Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 118069700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Cogent Biosciences Inc Net Assets Breakdown (December 2025)
Cogent Biosciences Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $161.00K | 0.03% |
| Other Comprehensive Income | $355.00K | 0.06% |
| Other Components | $1.82 Billion | 286.67% |
| Total Equity | $636.37 Million | 100.00% |
Cogent Biosciences Inc Competitors by Market Cap
The table below lists competitors of Cogent Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Compagnie Generale des Etablissements Michelin SCA
LSE:0OFM
|
$5.04 Billion |
|
Xometry Inc
NASDAQ:XMTR
|
$5.04 Billion |
|
Enstar Group Limited
NASDAQ:ESGR
|
$5.04 Billion |
|
Luzerner Kantonalbank AG
SW:LUKN
|
$5.04 Billion |
|
Camtek Ltd
TA:CAMT
|
$5.03 Billion |
|
Parkland Fuel Corporation
TO:PKI
|
$5.03 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
$5.03 Billion |
|
Bumrungrad Hospital PCL
BK:BH
|
$5.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cogent Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 256,286,000 to 636,371,000, a change of 380,085,000 (148.3%).
- Net loss of 328,937,000 reduced equity.
- New share issuances of 159,323,000 increased equity.
- Other comprehensive income decreased equity by 92,000.
- Other factors increased equity by 549,791,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-328.94 Million | -51.69% |
| Share Issuances | $159.32 Million | +25.04% |
| Other Comprehensive Income | $-92.00K | -0.01% |
| Other Changes | $549.79 Million | +86.39% |
| Total Change | $- | 148.31% |
Book Value vs Market Value Analysis
This analysis compares Cogent Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $9.40 | $31.02 | x |
| 2016-12-31 | $7.08 | $31.02 | x |
| 2017-12-31 | $3.83 | $31.02 | x |
| 2018-12-31 | $9.68 | $31.02 | x |
| 2019-12-31 | $4.17 | $31.02 | x |
| 2020-12-31 | $21.18 | $31.02 | x |
| 2021-12-31 | $5.53 | $31.02 | x |
| 2022-12-31 | $4.35 | $31.02 | x |
| 2023-12-31 | $3.24 | $31.02 | x |
| 2024-12-31 | $2.47 | $31.02 | x |
| 2025-12-31 | $9.41 | $31.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cogent Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -51.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.47x
- Recent ROE (-51.69%) is above the historical average (-57.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -9.48% | -220.76% | 0.03x | 1.36x | $-13.54 Million |
| 2016 | -34.60% | -285.19% | 0.08x | 1.44x | $-23.36 Million |
| 2017 | -90.06% | -304.93% | 0.17x | 1.74x | $-28.32 Million |
| 2018 | -57.33% | -354.76% | 0.11x | 1.43x | $-40.56 Million |
| 2019 | -95.31% | -134.55% | 0.46x | 1.56x | $-33.45 Million |
| 2020 | -31.88% | -950.43% | 0.03x | 1.07x | $-98.27 Million |
| 2021 | -33.74% | 0.00% | 0.00x | 1.08x | $-93.69 Million |
| 2022 | -51.87% | 0.00% | 0.00x | 1.18x | $-158.22 Million |
| 2023 | -74.63% | 0.00% | 0.00x | 1.22x | $-218.19 Million |
| 2024 | -99.83% | 0.00% | 0.00x | 1.28x | $-281.49 Million |
| 2025 | -51.69% | 0.00% | 0.00x | 1.47x | $-392.57 Million |
Industry Comparison
This section compares Cogent Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cogent Biosciences Inc (COGT) | $636.37 Million | -9.48% | 0.47x | $5.03 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more